Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 14/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055351 | 0.96 | IL2 (0.42) | IL2KAT6ASTIM1ORAI1ORAI2 | |
| SCHEMBL3109398 | 0.89 | IL2 (0.41) | IL2KAT6AMEN1KMT2ARORC | |
| SCHEMBL3105832 | 0.83 | IL2 (0.41) | IL2MEN1KMT2ARORCSTIM1 | |
| SCHEMBL3103400 | 0.80 | RAB9A (0.45) | IL2MEN1KMT2ARORC | |
| SCHEMBL3092144 | 0.78 | IL2 (0.46) | IL2RORCSTIM1ORAI1ORAI2 | |
| SCHEMBL8060869 | 0.78 | IL2 (0.41) | IL2 | |
| SCHEMBL647160 | 0.76 | IL2 (0.46) | IL2MEN1KMT2ARORC | |
| SCHEMBL8069094 | 0.76 | STIM1 (0.43) | IL2MEN1KMT2ASTIM1ORAI1 | |
| SCHEMBL451062 | 0.75 | IL2 (0.62) | IL2RAF1BRAF | |
| SCHEMBL11940274 | 0.73 | IL2 (0.41) | IL2MEN1KMT2ARORCSTIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273751-A1 | SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-28 | — | — | US | claimed |
| WO-2009038775-A1 | SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-03-26 | — | — | WO | claimed |
| US-8324219-B2 | Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100273751-A1 | SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2009038775-A1 | SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273751-A1 | SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, IL5, NLRP1 | IL2 9/4885KAT6A 2916/4885MEN1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.